Context: Because very few studies have examined the correlation between BRAF mutations
and clinicopathological features of papillary thyroid carcinoma (PTC), we analyzed here a …

Context: Use of BRAF mutation in papillary thyroid cancer (PTC) has the potential to improve
risk stratification of this cancer. Objective: The objective of the study was to investigate the …

Background: The BRAF mutation has been shown to be associated with aggressive
clinicopathologic characteristics of papillary thyroid cancer (PTC). However, several studies …

Context: BRAFV600E is considered a negative prognostic marker in papillary thyroid
carcinoma (PTC), but unexplained conflicting results are present in the literature. In light of …

BACKGROUND: The incidence of thyroid cancer has doubled over the past decade. The
reason for this dramatic increase in incidence is controversial. Some investigators have …

Background: The BRAF V600E mutation, the most frequent genetic alteration in papillary
thyroid carcinoma (PTC), was demonstrated to be a poor prognostic factor. The aim of this …

Abstract Background The BRAF V600E mutation is the most common genetic alteration
found in papillary thyroid cancer (PTC). Recent studies show that this mutation occurs more …

Background: The BRAFV600E mutation is the most frequent genetic alteration in papillary
thyroid carcinoma (PTC). The role of BRAFV600E mutation as a poor prognostic factor has …

BACKGROUND. Numerous studies have investigated the clinical significance of BRAF
mutation in papillary thyroid carcinoma (PTC). However, there have been conflicting data on …

Objective To investigate the mutant status of BRAF gene and analyze its relationship to
epidemiological risk factors and clinical outcomes among patients with papillary thyroid …